Gilead Sciences and Insistro Team Up to Develop Therapies for Nonalcoholic Fatty Liver Disease


Gilead Sciences (GILD) and privately held insistro said pre-market Tuesday they have entered into a three-year partnership to discover and develop therapies to treat nonalcoholic steatohepatitis (NASH).

Under the deal, insitro will leverage its proprietary platform to create disease models for NASH and discover targets that have an impact on the progression and regression of the disease. The partnership will utilize the insitro Human (ISH) platform which combines machine learning, human genetics and functional genomics to generate and optimize in vitro models and drive therapeutic discovery and development, both companies said.

Insitro will receive an upfront payment of $15 million and is entitled to additional near-term payments up to $35 million upon achievement of operational milestones. It will also be eligible to receive up to $200 million upon attainment of preclinical, development, regulatory and commercial milestones for each of the five Gilead targets and up to low double-digit tiered royalties on net sales.

For programs where insitro opts in, it will have the right to co-develop and co-detail in the US, receive a profit share in China and receive milestone payments and royalties on other ex-US sales, the companies said.